KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for Novavax (NVAX) over the last 8 years, with Dec 2024 value amounting to -$1.23.

  • Novavax's EPS (Weighted Average and Diluted) fell 64.47% to -$1.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.78, marking a year-over-year increase of 177.73%. This contributed to the annual value of -$1.23 for FY2024, which is 77.26% up from last year.
  • Latest data reveals that Novavax reported EPS (Weighted Average and Diluted) of -$1.23 as of FY2024, which was up 77.26% from -$5.41 recorded in FY2023.
  • In the past 5 years, Novavax's EPS (Weighted Average and Diluted) registered a high of -$1.23 during FY2024, and its lowest value of -$23.44 during FY2021.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$5.02, with a median of -$5.41 in 2023.
  • Per our database at Business Quant, Novavax's EPS (Weighted Average and Diluted) crashed by 222.42% in 2021 and then spiked by 77.26% in 2024.
  • Over the past 5 years, Novavax's EPS (Weighted Average and Diluted) (Yearly) stood at -$7.27 in 2020, then slumped by 222.42% to -$23.44 in 2021, then spiked by 64.08% to -$8.42 in 2022, then soared by 35.75% to -$5.41 in 2023, then soared by 77.26% to -$1.23 in 2024.